S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal

Natera (NTRA) Stock Price, News & Analysis

$94.47
-2.24 (-2.32%)
(As of 04/12/2024 ET)
Today's Range
$93.82
$97.16
50-Day Range
$68.40
$97.48
52-Week Range
$36.90
$98.82
Volume
959,947 shs
Average Volume
1.41 million shs
Market Capitalization
$11.41 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$85.73

Natera MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
9.2% Downside
$85.73 Price Target
Short Interest
Healthy
5.18% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.67mentions of Natera in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$28.55 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.35) to ($1.11) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.37 out of 5 stars

Medical Sector

756th out of 923 stocks

Medical Laboratories Industry

17th out of 19 stocks

NTRA stock logo

About Natera Stock (NASDAQ:NTRA)

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

NTRA Stock Price History

NTRA Stock News Headlines

Elon Musk Secret Crypto Plot Exposed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Elon Musk Secret Crypto Plot Exposed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Natera (NASDAQ:NTRA) Shares Gap Up to $92.36
See More Headlines
Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/13/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:NTRA
Fax
N/A
Employees
3,293
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$85.73
High Stock Price Target
$120.00
Low Stock Price Target
$66.00
Potential Upside/Downside
-9.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
14 Analysts

Profitability

Net Income
$-434,800,000.00
Pretax Margin
-40.14%

Debt

Sales & Book Value

Annual Sales
$1.08 billion
Book Value
$6.37 per share

Miscellaneous

Free Float
109,383,000
Market Cap
$11.41 billion
Optionable
Optionable
Beta
1.37
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

NTRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Natera stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NTRA shares.
View NTRA analyst ratings
or view top-rated stocks.

What is Natera's stock price target for 2024?

14 analysts have issued 12-month target prices for Natera's stock. Their NTRA share price targets range from $66.00 to $120.00. On average, they predict the company's share price to reach $85.73 in the next twelve months. This suggests that the stock has a possible downside of 9.2%.
View analysts price targets for NTRA
or view top-rated stocks among Wall Street analysts.

How have NTRA shares performed in 2024?

Natera's stock was trading at $62.64 on January 1st, 2024. Since then, NTRA shares have increased by 50.8% and is now trading at $94.47.
View the best growth stocks for 2024 here
.

Are investors shorting Natera?

Natera saw a decrease in short interest in March. As of March 31st, there was short interest totaling 6,250,000 shares, a decrease of 21.4% from the March 15th total of 7,950,000 shares. Based on an average trading volume of 1,520,000 shares, the days-to-cover ratio is presently 4.1 days.
View Natera's Short Interest
.

When is Natera's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our NTRA earnings forecast
.

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) posted its quarterly earnings results on Wednesday, February, 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping analysts' consensus estimates of ($0.73) by $0.09. The medical research company had revenue of $311.11 million for the quarter, compared to the consensus estimate of $300.38 million. Natera had a negative net margin of 40.16% and a negative trailing twelve-month return on equity of 62.19%.

What guidance has Natera issued on next quarter's earnings?

Natera issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.3 billion.

What is Steve Chapman's approval rating as Natera's CEO?

158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Natera own?
When did Natera IPO?

Natera (NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Who are Natera's major shareholders?

Natera's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Banque Cantonale Vaudoise (0.01%), Park Avenue Securities LLC (0.00%) and Fulton Bank N.A. (0.00%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, John Fesko, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens.
View institutional ownership trends
.

How do I buy shares of Natera?

Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NTRA) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners